Cipla Q2 FY27: margins improve, US annualised revenue target maintained

Management guided margin improvementInvestor Communications View source PDF Explain this filing

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹1378.90

prior close

₹1383.00

announcement price

After-mkt

timing

Nifty 100market+1.7%-1.7% vs market

Pharmaceuticals peers, median of 174sector+0.2%-0.2% vs sector

On the reaction day the stock moved 1.7 pts less than Nifty 100 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.3

15m

-0.2

30m

-0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+1.7-1.7+0.2-0.2

Next day

+0.9+3.2-2.3+0.6+0.3

+1.5+4.0-2.6+1.6-0.2

+1.6+6.4-4.8+2.3-0.7

+2.3pendingpending+2.2+0.1

—————

15d

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue was INR 7,404 crore, up 4% sequentially, and profit after tax was INR 878 crore. The margin before depreciation, interest and other income improved 200 basis points to 18.7%, and management guided to further sequential gains. North America revenue was $172 million; management maintained a $1 billion annualised exit revenue rate target, backed by Ventolin, Advair and three planned launches. One India grew 12% year on year.

Likely market impact

Positive: margin gains, India growth and US launch ramps could lift earnings, but approval timing and compliance issues may delay targets.